Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:13:42 ON 15 OCT 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:13:49 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   14 OCT 2008  HIGHEST RN 1061458-09-0
DICTIONARY FILE UPDATES:  14 OCT 2008  HIGHEST RN 1061458-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\11664190s12.str
```



```
chain nodes :
7  8  9  10  11  12  13  14  15  17
ring nodes :
1  2  3  4  5  6  16  18  19  20  21  22
chain bonds :
1-7  4-13  7-8  7-9  7-10  10-11  11-12  13-14  14-15  15-16  15-17
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  16-18  16-22  18-19  19-20  20-21  21-22
exact/norm bonds :
1-2  1-6  1-7  2-3  3-4  4-5  5-6  7-8  7-9  7-10  13-14  14-15  15-17
exact bonds :
4-13  10-11  11-12  15-16
normalized bonds :
16-18  16-22  18-19  19-20  20-21  21-22


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:CLASS  13:CLASS  14:CLASS  15:CLASS  16:Atom  17:CLASS  18:Atom
19:Atom  20:Atom  21:Atom  22:Atom



L1      STRUCTURE UPLOADED

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:14:05 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       30 TO ITERATE

100.0% PROCESSED       30 ITERATIONS                                 12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          272 TO      928
PROJECTED ANSWERS:              33 TO      447

L2           12 SEA SSS SAM L1

=> s l1 sss full
```

FULL SEARCH INITIATED 16:14:11 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 532 TO ITERATE

100.0% PROCESSED 532 ITERATIONS 178 ANSWERS
SEARCH TIME: 00.00.01

L3 178 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 178.36 178.57

FILE 'CAPLUS' ENTERED AT 16:14:15 ON 15 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Oct 2008 VOL 149 ISS 16
FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l3
L4 11 L3

=> d ibib abs hitstr 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:509742 CAPLUS
DOCUMENT NUMBER: 146:500900
TITLE: Preparation of piperidine glycine transporter inhibitors
INVENTOR(S): Hallett, David; Lindsley, Craig W.; Naylor, Elizabeth M.; Zhao, Zhijian; Theberge, Cory R.; Wolkenberg, Scott E.; Nolt, Brad M.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2007053400	A2	20070510	WO 2006-US41699	20061027
WO 2007053400	A3	20070920		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006309050	A1	20070510	AU 2006-309050	20061027
CA 2627177	A1	20070510	CA 2006-2627177	20061027
EP 1942893	A2	20080716	EP 2006-826685	20061027

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2005-731010P P 20051028
WO 2006-US41699 W 20061027

OTHER SOURCE(S): MARPAT 146:500900

GI



I



II

AB The title compds. I [R1 = (CH2)nR1a (wherein n = 0-6; R1a = (un)substituted alkyl, cycloalkyl, piperidinyl, etc.); R2 = (un)substituted Ph, heterocyclyl, cycloalkyl, etc.; R3 = (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, etc.; R4, R5 = H, alkyl; or R4 and R5 taken together form a cycloalkyl ring; A = O, NR10 (R10 = H, alkyl, cycloalkyl, etc.); m = 0 or 1] that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved, were prepared E.g., a multi-step synthesis of II, starting from tert-Bu 4-cyanopiperidine-1-carboxylate and cyclopropylmethyl bromide, was given. The exemplified compds. I had activity in inhibiting specific uptake of [14C]glycine, generally with an IC50 value of less than about 10 μM. Pharmaceutical composition comprising the compound I is disclosed.

IT 936481-32-2P 936481-37-7P 936481-39-9P
936481-41-3P 936481-42-4P 936481-43-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of piperidine glycine transporter inhibitors)

RN 936481-32-2 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[1'-(propylsulfonyl)[1,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)



RN 936481-37-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936481-39-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(4-methyl-1-piperazinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936481-41-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)



RN 936481-42-4 CAPLUS
CN Benzamide, N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 936481-43-5 CAPLUS
CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-methyl-1'-(propylsulfonyl)[2,4'-bipiperidin]-4'-yl]methyl]- (CA INDEX NAME)



L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:410347 CAPLUS
DOCUMENT NUMBER: 146:421847
TITLE: Preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1 glycine transporter inhibitors for diagnostic imaging
INVENTOR(S): Burns, H. Donald; Hamill, Terence G.; Lindsley, Craig W.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 30pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007041025	A2	20070412	WO 2006-US36989	20060925
WO 2007041025	A3	20070830		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1942733	A2	20080716	EP 2006-815187	20060925

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.:	US 2005-721782P	P	20050929
	WO 2006-US36989	W	20060925

OTHER SOURCE(S): MARPAT 146:421847

GI



I



II

AB Title compds. (I; A = N, CH; R2a, R2b = H, F, Cl, Br; R3 = alkyl, fluoroalkyl; R4 = H, alkyl; 1 of X, Y = 18F, O11CH3, OCD218F, the other = H), were prepared Thus, title compound (II) was prepared by treatment of the corresponding phenol derivative with a product prepared from [18F]F- and CD2Br2 in the presence of Cs2CO3 in DMF at 100°.

IT 934200-18-7P 934200-19-8P 934200-20-1P
934200-21-2P
RL: DGN (Diagnostic use); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1 glycine transporter inhibitors for diagnostic imaging)

RN 934200-18-7 CAPLUS

CN Benzamide, 2-fluoro-6-(fluoro-18F-methoxy-d2)-N-[(1S)-1-[4-phenyl-1-

(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 934200-19-8 CAPLUS
CN Benzamide, 2-chloro-6-(fluoro-18F)-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 934200-20-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[3-(methoxy-11C)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 934200-21-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[6-(fluoro-18F)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 934200-22-3 934200-23-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1 glycine transporter inhibitors for diagnostic imaging)
RN 934200-22-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 934200-23-4 CAPLUS
CN Benzamide, 2,6-dichloro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 866559-78-6P 866559-80-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of radiolabeled benzoic acid piperidinylalkylamide GlyT1 glycine transporter inhibitors for diagnostic imaging)
RN 866559-78-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(6-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-

piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-80-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-hydroxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:344575 CAPLUS
DOCUMENT NUMBER: 146:492593
TITLE: Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides
AUTHOR(S): Lindsley, Craig W.; Zhao, Zhijian; Leister, William H.; O'Brien, Julie; Lemaire, Wei; Williams, David L., Jr.; Chen, Tsing-Bau; Chang, Raymond S. L.; Burno, Maryann; Jacobson, Marlene A.; Sur, Cyrille; Kinney, Gene G.; Pettibone, Douglas J.; Tiller, Philip R.; Smith, Sheri; Tsou, Nancy N.; Duggan, Mark E.; Conn, P. Jeffrey; Hartman, George D.
CORPORATE SOURCE: Department of Medicinal Chemistry, Technology Enabled Synthesis Group, Merck Research Laboratories, West Point, PA, 19486, USA
SOURCE: ChemMedChem (2006), 1(8), 807-811
CODEN: CHEMGX; ISSN: 1860-7179
PUBLISHER: Wiley-VCH Verlag GmbH & Co. KGaA
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:492593
GI



I

AB An iterative analog library synthesis approach was employed to develop SAR for the title compds. Analog I was thus identified as a novel, centrally active GlyT1 inhibitor. I enhanced prepulse inhibition in a rodent behavioral model sensitive to antipsychotic treatment.

IT 852029-09-5P 852029-12-0P 852029-23-3P
852029-28-8P 852029-36-8P 852029-37-9P
852029-44-8P 852029-47-1P 852029-48-2P
852029-50-6P 936101-97-2P 936101-98-3P
936101-99-4P 936102-00-0P 936102-01-1P
936102-02-2P 936102-03-3P 936102-04-4P
936102-05-5P 936102-06-6P 936102-07-7P
936102-08-8P 936102-09-9P 936102-10-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(piperidinylmethylbenzamide-derived glycine transporter-1 inhibitors)

RN 852029-09-5 CAPLUS

CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS

CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-44-8 CAPLUS
CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-47-1 CAPLUS
CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-48-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-50-6 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936101-97-2 CAPLUS
CN Benzamide, 2,4-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936101-98-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 936101-99-4 CAPLUS
CN Benzamide, 2-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-00-0 CAPLUS
CN Benzamide, 2-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-01-1 CAPLUS
CN Benzamide, 2,4-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-02-2 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-03-3 CAPLUS
CN Benzamide, N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-04-4 CAPLUS
CN Benzamide, N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-05-5 CAPLUS
CN Benzamide, 2-chloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-06-6 CAPLUS
CN Benzamide, 2-fluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-07-7 CAPLUS
CN Benzamide, 2,4-difluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-08-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-09-9 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 936102-10-2 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[(1R)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 266341-42-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(piperidinylmethylbenzamide-derived glycine transporter-1 inhibitors)
RN 266341-42-8 CAPLUS
CN Benzamide, 2-methoxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1190066 CAPLUS
DOCUMENT NUMBER: 146:142582
TITLE: Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-

(propylsulfonyl)piperidin-4-yl)methyl)benzamides

AUTHOR(S): Zhao, Zhijian; O'Brien, Julie A.; Lemaire, Wei; Williams, David L.; Jacobson, Marlene A.; Sur, Cyrille; Pettibone, Doug J.; Tiller, Philip R.; Smith, Sheri; Hartman, George D.; Wolkenberg, Scott E.; Lindsley, Craig W.

CORPORATE SOURCE: Department of Medicinal Chemistry, Merck and Co., Inc., West Point, PA, 19486, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(23), 5968-5972
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 146:142582

GI



I

AB The synthesis and SAR of potent and selective non-sarcosine-derived GlyT1 inhibitors is described. A library of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides was constructed using amidation as the key step. Some compds., e.g., I, displayed promising GlyT1 inhibitory activity.

IT 919284-93-8P 919284-94-9P
RL: PAC (Pharmacological activity); PRP (Properties); PUR (Purification or recovery); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, GlyT1 inhibitory activity and SAR of [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides starting from N-Boc cyanopiperidine using amidation as key steps)

RN 919284-93-8 CAPLUS

CN Benzamide, 2,4-dichloro-N-[(1R)-1-[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 919284-94-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 869463-15-0P 869463-16-1P 919284-71-2P
919284-72-3P 919284-73-4P 919284-74-5P
919284-75-6P 919284-76-7P 919284-77-8P
919284-80-3P 919284-81-4P 919284-82-5P
919284-83-6P 919284-84-7P 919284-85-8P
919284-86-9P 919284-87-0P 919284-88-1P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, GlyT1 inhibitory activity and SAR of [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides starting from N-Boc cyanopiperidine using amidation as key steps)
RN 869463-15-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 869463-16-1 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-71-2 CAPLUS
CN 4-Piperidinecarboxamide, 4-[[(2,4-dichlorobenzoyl)amino]methyl]-N,N-dimethyl-1-(propylsulfonyl)- (CA INDEX NAME)



RN 919284-72-3 CAPLUS
CN 4-Piperidinecarboxamide, 4-[[(2,4-dichlorobenzoyl)amino]methyl]-N-ethyl-1-

(propylsulfonyl)- (CA INDEX NAME)



RN 919284-73-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[[3-(dimethylamino)-1-pyrrolidinyl]carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-74-5 CAPLUS
CN 4-Piperidinecarboxamide, N-cyclopropyl-4-[[(2,4-dichlorobenzoyl)amino]methyl]-1-(propylsulfonyl)- (CA INDEX NAME)



RN 919284-75-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[(4-methyl-1-piperazinyl)carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-76-7 CAPLUS
CN 4-Piperidinecarboxamide, 4-[[(2,4-dichlorobenzoyl)amino]methyl]-N-[(3-methyl-3-oxetanyl)methyl]-1-(propylsulfonyl)- (CA INDEX NAME)



RN 919284-77-8 CAPLUS
CN Benzamide, N-[[4-[(3-amino-1-azetidinyl)carbonyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]-2,4-dichloro- (CA INDEX NAME)



RN 919284-80-3 CAPLUS
CN Benzamide, N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-81-4 CAPLUS
CN Benzamide, N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 919284-82-5 CAPLUS
CN Benzamide, 2-chloro-4-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-83-6 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 919284-84-7 CAPLUS
CN Benzamide, 4-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 919284-85-8 CAPLUS
CN Benzamide, 3-chloro-2,6-difluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-86-9 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-87-0 CAPLUS
CN Benzamide, 2,4-dichloro-5-fluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-88-1 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 919284-68-7P 919284-69-8P 919284-70-1P
919284-90-5P 919284-91-6P 919284-92-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, GlyT1 inhibitory activity and SAR of [morpholinecarbonyl(propylsulfonyl)piperidinylmethyl]benzamides starting from N-Boc cyanopiperidine using amidation as key steps)

RN 919284-68-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[(phenylmethoxy)methyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-69-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(hydroxymethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 919284-70-1 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[[(2,4-dichlorobenzoyl)amino]methyl]-1-(propylsulfonyl)- (CA INDEX NAME)



RN 919284-90-5 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[4-[(phenylmethoxy)methyl]-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 919284-91-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[4-(hydroxymethyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 919284-92-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 4-[1-[(2,4-dichlorobenzoyl)amino]ethyl]-1-(propylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1093266 CAPLUS
DOCUMENT NUMBER: 145:432223

TITLE: Method of treating schizophrenia prodrome
INVENTOR(S): Woods, Scott W.
PATENT ASSIGNEE(S): Yale University, USA
SOURCE: PCT Int. Appl., 64pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006110724	A2	20061019	WO 2006-US13444	20060411
WO 2006110724	A3	20070322		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006235400	A1	20061019	AU 2006-235400	20060411
CA 2602626	A1	20061019	CA 2006-2602626	20060411
EP 1871165	A2	20080102	EP 2006-740849	20060411
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2008535864	T	20080904	JP 2008-505637	20060411
PRIORITY APPLN. INFO.:			US 2005-670600P P	20050411
			WO 2006-US13444 W	20060411

OTHER SOURCE(S): MARPAT 145:432223

AB The present invention relates to a method of treating schizophrenia prodrome in human subjects using a NMDA glycine site agonist, a glycine transporter-1 inhibitor or mixts. thereof, optionally in combination with a pharmaceutically acceptable additive, carrier or excipient.

IT 852029-09-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(method of treating schizophrenia prodrome with NMDA glycine agonist and glycine transporter-1 inhibitor)

RN 852029-09-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:342953 CAPLUS
DOCUMENT NUMBER: 144:369920
TITLE: Cyclopropyl piperidine glycine transporter inhibitors for treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Wolkenberg, Scott E.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006039221	A2	20060413	WO 2005-US34301		20050926
WO 2006039221	A3	20060908			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2005292323	A1	20060413	AU 2005-292323		20050926
CA 2581582	A1	20060413	CA 2005-2581582		20050926
EP 1797035	A2	20070620	EP 2005-801197		20050926
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 101031547	A	20070905	CN 2005-80033117		20050926
JP 2008514705	T	20080508	JP 2007-534679		20050926
BR 2005015954	A	20080812	BR 2005-15954		20050926
IN 2007DN01977	A	20070817	IN 2007-DN1977		20070314
US 20080108663	A1	20080508	US 2007-664190		20070328
MX 200703816	A	20070424	MX 2007-3816		20070329
KR 2007058565	A	20070608	KR 2007-707362		20070330
NO 2007002208	A	20070427	NO 2007-2208		20070427
PRIORITY APPLN. INFO.:			US 2004-614942P	P	20040930
			WO 2005-US34301	W	20050926

OTHER SOURCE(S): MARPAT 144:369920
GI



I

AB The present invention is directed to cyclopropyl piperidine compds. (I; R1 = substituted Ph, substituted heterocycle, (un)substituted C1-8 alkyl, (un)substituted C3-6 cycloalkyl; R2 = (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl; R3,R4 = H, (un)substituted C1-6 alkyl; A = O, NR5; R5 = H, (un)substituted C1-6 alkyl, (un)substituted C3-6 cycloalkyl, benzyl, phenyl; m = 0, 1) that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

IT 882034-97-1P 882034-98-2P 882035-07-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclopropyl piperidine compds. as glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 882034-97-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 882034-98-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-6-fluoro- (CA INDEX NAME)



RN 882035-07-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(cyclopropylmethyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1220538 CAPLUS
DOCUMENT NUMBER: 143:472603
TITLE: Morpholinyl piperidine derivative glycine transporter GlyT1 inhibitors, their preparation/., and their use for treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wolkenberg, Scott E.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005107469	A2	20051117	WO 2005-US15134	20050429
WO 2005107469	A3	20060629		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070249606	A1	20071025	US 2006-579234	20061030
PRIORITY APPLN. INFO.:			US 2004-568201P	P 20040505
			WO 2005-US15134	W 20050429

OTHER SOURCE(S): MARPAT 143:472603
GI



I

AB The invention discloses morpholinyl piperidine compds. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved. Preparation of I is described.

IT 869463-15-0P 869463-16-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(morpholinyl piperidine derivative glycine transporter GlyT1 inhibitor preparation and use for treatment of neurol. and psychiatric disorders)

RN 869463-15-0 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 869463-16-1 CAPLUS

CN Benzamide, 2-chloro-N-[[4-(4-morpholinylcarbonyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1103490 CAPLUS
DOCUMENT NUMBER: 143:386922
TITLE: Preparation of heteroaryl-substituted piperidine glycine transporter inhibitors for the treatment of psychiatric disorders
INVENTOR(S): Blackaby, Wesley; Duggan, Mark E.; Hallett, David; Hartman, George D.; Jennings, Andrew S.; Leister, William H.; Lewis, Richard T.; Lindsley, Craig W.; Naylor, Elizabeth; Street, Leslie J.; Wang, Yi; Wisnoski, David D.; Wolkenberg, Scott E.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Merck Sharp & Dohme Limited
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005094514	A2	20051013	WO 2005-US9810	20050323
WO 2005094514	A3	20060420		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005228133	A1	20051013	AU 2005-228133	20050323
CA 2560256	A1	20051013	CA 2005-2560256	20050323
EP 1729772	A2	20061213	EP 2005-726105	20050323
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
CN 1933836	A	20070321	CN 2005-80009593	20050323
JP 2007530576	T	20071101	JP 2007-505167	20050323

IN 2006CN03155	A	20070608	IN 2006-CN3155		20060831
US 20070254880	A1	20071101	US 2007-593950		20070510
PRIORITY APPLN. INFO.:			US 2004-555925P	P	20040324
			WO 2005-US9810	W	20050323

OTHER SOURCE(S): CASREACT 143:386922; MARPAT 143:386922

GI



I



II

AB Title compds. I [R1 = H, alkyl, halo, Ph, etc.; R2 = (un)substituted Ph, heterocyclyl, alkyl, etc.; R3 = alkyl, cycloalkyl, etc.; R4-5 = H, alkyl, etc.; R6 = H, alkyl; W, X, Y, Z = C, N with the proviso that at least two of W, X, Y and Z are C, to form a pyridine, oxodihydropyridine, etc.; A = O, (un)substituted N; m = 0-1] are prepared For instance, II is prepared in 5 steps from 2-fluoropyridine, tert-Bu 4-cyanopiperidine-1-carboxylate, n-PrSO2Cl and 2-chloro-3,6-difluorobenzoyl chloride. I inhibit the glycine transporter GlyT1 [no data] and are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine transporter GlyT1 is involved.

IT 866559-77-5P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of heteroaryl-substituted piperidine glycine transporter inhibitors for treatment of psychiatric disorders)

RN 866559-77-5 CAPLUS

CN Benzamide, 2,4-dichloro-N-[[4-(6-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



IT 866558-67-0P 866558-68-1P 866558-69-2P
866558-71-6P 866558-72-7P 866558-73-8P
866558-74-9P 866558-75-0P 866558-76-1P
866558-77-2P 866558-78-3P 866558-79-4P
866558-80-7P 866558-81-8P 866558-82-9P
866558-83-0P 866558-84-1P 866558-85-2P
866558-86-3P 866558-87-4P 866558-93-2P
866558-94-3P 866558-95-4P 866558-96-5P
866558-99-8P 866559-00-4P 866559-01-5P
866559-02-6P 866559-10-6P 866559-11-7P
866559-12-8P 866559-13-9P 866559-14-0P
866559-15-1P 866559-16-2P 866559-17-3P
866559-29-7P 866559-30-0P 866559-31-1P
866559-32-2P 866559-45-7P 866559-46-8P
866559-48-0P 866559-49-1P 866559-50-4P
866559-54-8P 866559-55-9P 866559-56-0P
866559-57-1P 866559-59-3P 866559-62-8P
866559-64-0P 866559-71-9P 866559-75-3P
866559-76-4P 866559-78-6P 866559-79-7P
866559-80-0P 866559-81-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl-substituted piperidine glycine transporter inhibitors for treatment of psychiatric disorders)

RN 866558-67-0 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-68-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 866558-69-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-71-6 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866558-72-7 CAPLUS
CN Benzamide, 2-chloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-73-8 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-74-9 CAPLUS
CN Benzamide, 2-bromo-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-75-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-76-1 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-77-2 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-78-3 CAPLUS
CN Benzamide, 2-fluoro-6-methoxy-N-[[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-79-4 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-80-7 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-6-(trifluoromethyl)- (CA INDEX NAME)



RN 866558-81-8 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-82-9 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-83-0 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-84-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-85-2 CAPLUS
CN Benzamide, 2-chloro-4-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-86-3 CAPLUS
CN Benzamide, 4-chloro-2-fluoro-N-[[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-87-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(4-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-93-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(3-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-94-3 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[1-(propylsulfonyl)-4-(3-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-95-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-96-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[1-(propylsulfonyl)-4-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866558-99-8 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-[6-(4-morpholinyl)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-00-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-[6-(4-morpholinyl)-2-pyridinyl]-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-01-5 CAPLUS
CN Benzamide, 2,4,5-trifluoro-N-[[4-(6-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-02-6 CAPLUS
CN Benzamide, 2,4-dichloro-5-fluoro-N-[[4-(6-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-10-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-11-7 CAPLUS
CN Benzamide, N-[1-methyl-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 866559-12-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-methyl-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-13-9 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[1-methyl-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-14-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866559-15-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[(1S)-1-[1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866559-16-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866559-17-3 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[(1S)-1-[4-(6-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 866559-29-7 CAPLUS
CN Benzamide, 2-chloro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-30-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-31-1 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-32-2 CAPLUS
CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-(propylsulfonyl)-4-(4-pyrimidinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-45-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-46-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-[6-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-48-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-[4-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-49-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-50-4 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-methoxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-54-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-(propylsulfonyl)-4-(2-pyrazinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-55-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[1-[(3-fluoropropyl)sulfonyl]-4-(2-pyridinyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-56-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-[(3-fluoropropyl)sulfonyl]-4-(2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-57-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-[(3-fluoropropyl)sulfonyl]-4-(3-fluoro-2-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-59-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-62-8 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[4-(3-fluoro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-64-0 CAPLUS
CN Benzamide, 2,4-dichloro-5-fluoro-N-[[1-(propylsulfonyl)-4-[6-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-71-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[1-[(3-fluoropropyl)sulfonyl]-4-[3-(trifluoromethyl)-2-pyridinyl]-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-75-3 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[4-(3-methyl-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 866559-76-4 CAPLUS
CN Benzamide, N-[[4-(3-bromo-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2,4-dichloro- (CA INDEX NAME)



RN 866559-78-6 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(6-chloro-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-79-7 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(1,6-dihydro-6-oxo-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-80-0 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[4-(3-hydroxy-2-pyridinyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 866559-81-1 CAPLUS
CN Benzamide, 2,4-dichloro-N-[[(2R,4S)-2-methyl-1-(propylsulfonyl)-4-(2-pyridinyl)-4-piperidinyl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:451128 CAPLUS
DOCUMENT NUMBER: 142:476263
TITLE: 4-Phenylpiperidine derivative glycine transporter inhibitors for the treatment of neurological and psychiatric disorders
INVENTOR(S): Lindsley, Craig W.; Wisnoski, David D.; Zhao, Zhijian
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2005046601	A2	20050526	WO 2004-US37359		20041110
WO 2005046601	A3	20050818			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2004289290	A1	20050526	AU 2004-289290		20041110
CA 2544981	A1	20050526	CA 2004-2544981		20041110
EP 1684759	A2	20060802	EP 2004-810610		20041110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS					
CN 1878551	A	20061213	CN 2004-80033295		20041110
JP 2007512251	T	20070517	JP 2006-539749		20041110
IN 2006DN01895	A	20070615	IN 2006-DN1895		20060407
US 20070105902	A1	20070510	US 2006-579261		20060511
PRIORITY APPLN. INFO.:			US 2003-519348P	P	20031112
			WO 2004-US37359	W	20041110

OTHER SOURCE(S): MARPAT 142:476263
AB The invention discloses 4-phenylpiperidine derivs. that inhibit the glycine transporter GlyT1 and which are useful in the treatment of neurol. and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction and diseases in which the glycine

transporter GlyT1 is involved. Compound preparation is described.

IT 852029-09-5P 852029-11-9P 852029-12-0P
852029-13-1P 852029-16-4P 852029-17-5P
852029-18-6P 852029-21-1P 852029-22-2P
852029-23-3P 852029-24-4P 852029-25-5P
852029-26-6P 852029-27-7P 852029-28-8P
852029-31-3P 852029-32-4P 852029-33-5P
852029-34-6P 852029-35-7P 852029-36-8P
852029-37-9P 852029-38-0P 852029-39-1P
852029-40-4P 852029-41-5P 852029-42-6P
852029-43-7P 852029-44-8P 852029-46-0P
852029-47-1P 852029-48-2P 852029-49-3P
852029-50-6P 852029-51-7P 852029-52-8P
852029-53-9P 852029-54-0P 852029-55-1P
852029-56-2P 852029-57-3P 852029-58-4P
852029-59-5P 852029-60-8P 852029-61-9P
852029-62-0P 852029-63-1P 852029-64-2P
852029-65-3P 852029-66-4P 852029-67-5P
852029-68-6P 852029-69-7P 852029-70-0P
852029-71-1P 852029-72-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(phenylpiperidine derivative glycine transporter inhibitors for treatment of neurol. and psychiatric disorders)

RN 852029-09-5 CAPLUS
CN Benzamide, 2-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-11-9 CAPLUS
CN Benzamide, 4-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-12-0 CAPLUS
CN Benzamide, 2-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-13-1 CAPLUS
CN Benzamide, 2-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-16-4 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-17-5 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-18-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-21-1 CAPLUS
CN Benzamide, 2,3-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-22-2 CAPLUS
CN Benzamide, 3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-23-3 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-24-4 CAPLUS
CN Benzamide, 2-chloro-3,6-difluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-25-5 CAPLUS
CN Benzamide, 2-(difluoromethoxy)-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-26-6 CAPLUS
CN Benzamide, 2,5-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-27-7 CAPLUS
CN Benzamide, 2,6-dichloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-28-8 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-31-3 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-32-4 CAPLUS
CN Benzamide, 2-chloro-6-methyl-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-33-5 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-34-6 CAPLUS
CN Benzamide, 2-(2,2-difluoroacetyl)-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)



RN 852029-35-7 CAPLUS
CN Benzamide, 2-bromo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-36-8 CAPLUS
CN Benzamide, 2-amino-6-fluoro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-37-9 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-38-0 CAPLUS
CN Benzamide, 2-amino-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-4-(trifluoromethyl)- (CA INDEX NAME)



RN 852029-39-1 CAPLUS
CN Benzamide, 2-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-40-4 CAPLUS
CN Benzamide, 2-fluoro-6-iodo-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-41-5 CAPLUS
CN Benzamide, 2-(2,2-difluoroacetyl)-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-42-6 CAPLUS
CN Benzamide, 2-[(difluoromethyl)thio]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-43-7 CAPLUS
CN Benzamide, 2,3-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-44-8 CAPLUS
CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-(trifluoromethoxy)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-46-0 CAPLUS
CN Benzamide, 2,5-difluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-47-1 CAPLUS
CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-48-2 CAPLUS
CN Benzamide, 2,4-dichloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-49-3 CAPLUS
CN Benzamide, 2-fluoro-6-hydroxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-50-6 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-51-7 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-52-8 CAPLUS
CN Benzamide, 2-bromo-3-fluoro-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-53-9 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-54-0 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-55-1 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-56-2 CAPLUS
CN Benzamide, N-[[4-(4-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-(methylthio)- (CA INDEX NAME)



RN 852029-57-3 CAPLUS
CN Benzamide, N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 852029-58-4 CAPLUS
CN Benzamide, 2-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-59-5 CAPLUS
CN Benzamide, 4-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-60-8 CAPLUS
CN Benzamide, 2,6-dichloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-61-9 CAPLUS
CN Benzamide, 2,4-dichloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-62-0 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]propyl]- (CA INDEX NAME)



RN 852029-63-1 CAPLUS
CN Benzamide, N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-64-2 CAPLUS
CN Benzamide, 2-chloro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-65-3 CAPLUS
CN Benzamide, 2,6-difluoro-N-[[4-(3-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-66-4 CAPLUS
CN Benzamide, 2-amino-6-chloro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-67-5 CAPLUS
CN Benzamide, 2-chloro-6-fluoro-N-[[4-(2-fluorophenyl)-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-68-6 CAPLUS
CN Benzamide, N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)



RN 852029-69-7 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 852029-70-0 CAPLUS
CN Benzamide, N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]-2-[[(2,2,2-trifluoroethyl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-71-1 CAPLUS
CN Benzamide, 2-[[[2-(diethylamino)ethyl]amino]methyl]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852029-72-2 CAPLUS
CN Benzamide, 2-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]-N-[(1S)-1-[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:855758 CAPLUS
DOCUMENT NUMBER: 139:364829
TITLE: Preparation of heterocyclo inhibitors of potassium channel function
INVENTOR(S): Lloyd, John; Jeon, Yoon T.; Finlay, Heather; Yan, Lin; Beaudoin, Serge; Gross, Michael F.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; Icagen, Inc.
SOURCE: PCT Int. Appl., 330 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088908	A2	20031030	WO 2003-US11807	20030416
WO 2003088908	A3	20040527		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003223651	A1	20031103	AU 2003-223651		20030416
EP 1501467	A2	20050202	EP 2003-719792		20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005529114	T	20050929	JP 2003-585661		20030416
NO 2004004351	A	20041013	NO 2004-4351		20041013
PRIORITY APPLN. INFO.:			US 2002-374279P	P	20020419
			WO 2003-US11807	W	20030416

OTHER SOURCE(S): MARPAT 139:364829

GI



I



II

AB The title compds. [I; m, p = 0-3 (provided that the sum of m and p is at least 2); Q = NR1, O, S, SO, SO2; R1 = H, C(:W)NR6R7, SO2NR6R7, OCONR6R7, etc.; R2 = heteroaryl, heteroarylalkyl, aryl, etc.; J = a bond, alkylene; R3 = R5, OR5, SO2R5, etc.; R5 = CN, heteroaryl, aryl, etc.; R6, R7 = H, alkyl, OH, etc.; W = (un)substituted NH, N(CO2H), N(CN), N(SO2H), CH(NO2); Rx = H, alkyl, hydroxyalkyl, aryl, etc.], useful as inhibitors of potassium channel function (especially inhibitors of the Kv1 subfamily of voltage gated K+ channels, especially inhibitors Kv1.5 which has been linked to the ultra-rapidly activating delayed rectifier K+ current IKur) in the prevention and treatment of arrhythmia and IKur-associated conditions, were prepared E.g., a multi-step synthesis of II [starting from bis(2-chloroethyl)amine], was given. Pharmaceutical composition comprising the compound I is claimed.

IT 619277-83-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of substituted piperidines as inhibitors of potassium channel function)

RN 619277-83-7 CAPLUS

CN Benzamide, 2-methoxy-N-[[1-(propylsulfonyl)-4-(2-thienyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:314546 CAPLUS
DOCUMENT NUMBER: 132:321801
TITLE: Preparation of 4-[(benzoylamino)methyl]piperidines and analogs as potassium channel inhibitors
INVENTOR(S): Bao, Jianming; Kayser, Frank; Kotliar, Andrew; Parsons, William H.; Rupprecht, Kathleen M.; Claiborne, Christopher F.; Liverton, Nigel; Claremon, David A.; Thompson, Wayne J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2000025786	A1	20000511	WO 1999-US25066		19991026
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
US 6303637	B1	20011016	US 1999-422500		19991021
CA 2348735	A1	20000511	CA 1999-2348735		19991026
CA 2348735	C	20071211			
EP 1126849	A1	20010829	EP 1999-955169		19991026
EP 1126849	B1	20050309			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO					
JP 2002528503	T	20020903	JP 2000-579227		19991026
AU 764515	B2	20030821	AU 2000-11338		19991026
AT 290382	T	20050315	AT 1999-955169		19991026
PRIORITY APPLN. INFO.:			US 1998-106292P	P	19981030
			WO 1999-US25066	W	19991026

OTHER SOURCE(S): MARPAT 132:321801
GI



I

AB Title compds. [I; R1 = CH2NR10COR6; R2,R6 = (un)substituted Ph; R3,R4 = H, halo, alkyl, acyl, etc.; R10 = H, alkyl, acyl, etc.; Z = O, SO0-2, NR5; R5 = H, OH, alkyl, acyl, etc.; Z1,Z2 = bond, CH2, CH2CH2] were prepared as potassium channel inhibitors (no data). Thus, 4-cyano-1-benzyl-4-phenylpiperidine was reduced and the product N-acylated by 2-(MeO)C6H4COCl to give, after deprotection and Ac2O acylation, 2-(MeO)C6H4CONHCH2Z3Ac (Z3 = 4-phenylpiperidine-4,1-diyl).

IT 266341-42-8P 266341-43-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4-[(benzoylamino)methyl]piperidines and analogs as potassium channel inhibitors)

RN 266341-42-8 CAPLUS
CN Benzamide, 2-methoxy-N-[[4-phenyl-1-(propylsulfonyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 266341-43-9 CAPLUS
CN Benzamide, N-[[1-(butylsulfonyl)-4-phenyl-4-piperidinyl]methyl]-2-methoxy- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	64.75	243.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-8.80	-8.80

STN INTERNATIONAL LOGOFF AT 16:20:07 ON 15 OCT 2008